A gene editing firm has added $50 million to its coffers shortly after landing a significant development agreement with a global pharmaceutical company.
Durham biotech follows billion-dollar Novartis deal with $50M offering
A gene editing firm has added $50 million to its coffers shortly after landing a significant development agreement with a global pharmaceutical company.
About Our Site:
The primary purpose of the site is to provide Real Estate & Mortgage information as it relates to today’s business environment. It can also be used to answer related question you might have about buying, selling, or financing real estate.